Great Point Partners’s Tvardi Therapeutics TVRD Stock Holding History

Great Point Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,539	Closed	-$4.18M	–	45
2017 Q2	$4.18M	Buy	+7,539	New	+$4.78M	0.75%	29

Other funds holding TVRD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Great Point Partners's TVRD Position: Q3 2017 in Review

Great Point Partners sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 1,374 shares — an estimated $761K sold.

Great Point Partners first reported a position in TVRD in Q1 2014 and held it in 4 quarters. The position peaked at $3.41M in Q2 2014. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

Great Point Partners reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
Great Point Partners sold 1,374 Tvardi Therapeutics shares in Q3 2017, an estimated $761K.
Great Point Partners first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 4 quarters.
Great Point Partners's Tvardi Therapeutics position peaked at $3.41M in Q2 2014.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Great Point Partners's 13F filing for Q3 2017, filed 14 Nov 2017.